Stock data
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO) reported net income of -US$10.41M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | — | -US$10.41M | — |
| 2024 | — | — | — | -US$16.53M | — |
| 2023 | — | — | — | -US$13.07M | — |
| 2022 | — | — | — | -US$0.85M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$1.72M | — |
| 2026-03-31 | — | -US$0.99M | — |
| 2025-12-31 | — | -US$2.06M | — |
| 2025-09-30 | — | -US$1.10M | — |
| 2025-06-30 | — | -US$5.07M | — |
| 2025-03-31 | — | -US$2.18M | — |
| 2024-12-31 | — | -US$2.90M | — |
| 2024-09-30 | — | -US$5.99M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.